Leerink Partnrs Weighs in on CryoPort FY2027 Earnings

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of CryoPort in a research report issued to clients and investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda expects that the company will post earnings of ($0.59) per share for the year. The consensus estimate for CryoPort's current full-year earnings is ($0.99) per share.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. The business had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million.

Other research analysts also recently issued reports about the stock. UBS Group raised their price target on shares of CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Roth Mkm reissued a "buy" rating and issued a $15.00 price target on shares of CryoPort in a report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of CryoPort in a report on Thursday, May 8th. Morgan Stanley cut their price target on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Finally, BTIG Research cut their price target on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a report on Monday, July 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $10.88.

CryoPort Stock Performance

CryoPort stock traded down $0.24 during mid-day trading on Friday, reaching $7.19. The company's stock had a trading volume of 405,537 shares, compared to its average volume of 474,915. CryoPort has a 12-month low of $4.58 and a 12-month high of $9.78. The company has a market capitalization of $360.51 million, a P/E ratio of -3.07 and a beta of 1.89. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56. The firm's fifty day moving average price is $6.84 and its two-hundred day moving average price is $6.64.

Hedge Funds Weigh In On CryoPort

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. increased its position in shares of CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after buying an additional 2,120 shares during the period. Lazard Asset Management LLC bought a new stake in CryoPort during the fourth quarter worth about $51,000. Quarry LP bought a new stake in CryoPort during the fourth quarter worth about $69,000. Avanza Fonder AB boosted its stake in CryoPort by 31.4% during the second quarter. Avanza Fonder AB now owns 10,882 shares of the company's stock worth $81,000 after acquiring an additional 2,601 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in CryoPort by 548,750.0% during the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock worth $67,000 after acquiring an additional 10,975 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Insider Buying and Selling at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 13,321 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.01, for a total value of $93,380.21. Following the transaction, the director owned 73,056 shares in the company, valued at approximately $512,122.56. The trade was a 15.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the completion of the transaction, the chief executive officer owned 912,419 shares in the company, valued at $6,213,573.39. The trade was a 14.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 449,719 shares of company stock worth $3,042,327 in the last 90 days. 10.00% of the stock is owned by company insiders.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.